Loading...
AUROPHARMA Aurobindo Pharma Ltd Business Restructuring Announcement
Back
rbnd
RPHR
Aurobindo Pharma Ltd
(AUROPHARMA)
Follow
FY2023 Announcement
View More
Back
rbnd
RPHR
Aurobindo Pharma Ltd
(AUROPHARMA)
Follow
FY2023 Announcement
Filing:
Announcement
Published on:
29 Jun '23
GST Order Notice
30 Apr '25
Safety Incident
28 Apr '25
Positive CHMP Opinion
26 Apr '25
USFDA Approval
23 Apr '25
Product Approval
12 Apr '25
FDA Inspection Completed
11 Apr '25
Biosimilar Study Success
9 Apr '25
Marketing Authorization Gra...
5 Apr '25
Compliance Certificate
2 Apr '25
Cautionary Email
31 Mar '25
Cautionary Notice
28 Mar '25
Acquisition Update
28 Mar '25
Share Allotment
21 Mar '25
FDA Inspection Result
19 Mar '25
Investor Plant Visit
12 Mar '25
Investor Conference
11 Mar '25
License Agreement Termination
5 Mar '25
Investor Meeting
4 Mar '25
Tax Order Received
1 Mar '25
Acquisition Completed
28 Feb '25
Investor Plant Visit
20 Feb '25
FDA Inspection Update
20 Feb '25
Investor Meeting Notice
19 Feb '25
FDA Inspection Completed
18 Feb '25
Investor Plant Visit
18 Feb '25
Investor Plant Visit
17 Feb '25
Postal Ballot Notice
14 Feb '25
Zefylti® Approval
13 Feb '25
Q3 FY25 Earnings Call
13 Feb '25
Financial Results Publication
8 Feb '25
Director Re-appointment
6 Feb '25
Stake Acquisition
6 Feb '25
Investor Presentation
6 Feb '25
Q3 Financial Results
6 Feb '25
Aquisition of Tergene
6 Feb '25
GST Demand Order
5 Feb '25
Investor Meet Scheduled
4 Feb '25
Investor Meet Scheduled
4 Feb '25
Positive Opinion Received
31 Jan '25
Tax Recovery Orders
29 Jan '25
Earnings Call Scheduled
28 Jan '25
US FDA EIR Received
28 Jan '25
Compliance Certificate
6 Jan '25
NSE Warning Letter
28 Dec '24
Biosimilar Approval
21 Dec '24
FDA Inspection Completed
17 Dec '24
Regulatory Order Received
13 Dec '24
Biosimilar Approval
13 Dec '24
Director Retirement
13 Dec '24
Equity Share Allotment
11 Dec '24
USFDA Approval
5 Dec '24
Company Clarification
4 Dec '24
Investor Meeting
29 Nov '24
New Collaboration Agreement
23 Nov '24
Equity Share Transfer
22 Nov '24
Investor Meeting Notice
21 Nov '24
Earnings Call Transcript
18 Nov '24
Investor Meeting
13 Nov '24
GMP Certification Granted
12 Nov '24
Earnings Call Recording
11 Nov '24
Financial Results Released
11 Nov '24
Financial Results Correction
10 Nov '24
Investor Presentation
9 Nov '24
Financial Results Q2FY25
9 Nov '24
Investor Meeting
7 Nov '24
Earnings Call Schedule
4 Nov '24
New Facility Inauguration
29 Oct '24
Subsidiary Acquisition
25 Oct '24
Securities Update
7 Oct '24
Share Disposal
5 Oct '24
Stake Sale Completed
5 Oct '24
FDA Approval
1 Oct '24
FDA Inspection Completion
30 Sep '24
Investor Meeting
19 Sep '24
GLS Acquisition
18 Sep '24
FDA Inspection Report
18 Sep '24
Share Transfer Notice
13 Sep '24
FDA Approval Received
11 Sep '24
GST Demand Order
29 Aug '24
Investor Meetings
28 Aug '24
Buyback Completion
26 Aug '24
Buyback Announcement
21 Aug '24
Q1 FY25 Earnings Call
16 Aug '24
FDA Warning Letter
16 Aug '24
Investor Meeting
13 Aug '24
Investor Meeting
13 Aug '24
Investor Meet
13 Aug '24
Earnings Call Audio
12 Aug '24
Financial Results Published
12 Aug '24
Investor Presentation
10 Aug '24
Strong Q1 Results
10 Aug '24
USFDA Approval
6 Aug '24
Newspaper Advertisement
6 Aug '24
FDA Inspection Status
5 Aug '24
Earnings Call
5 Aug '24
Buyback Announcement
1 Aug '24
AGM via Video
31 Jul '24
Buyback Announcement
22 Jul '24
Certificate Submission
4 Jul '24
Acquisition Announcement
28 Jun '24
US FDA Inspection
27 Jun '24
Investor Meeting Participation
10 Jun '24
Investor Meeting
6 Jun '24
Investor Meeting
6 Jun '24
Investor Meeting
6 Jun '24
Investor Meet Participation
6 Jun '24
Investor Meeting
6 Jun '24
Earnings Call
31 May '24
Announcement
31 May '24
Investor Meet Participation
31 May '24
Earnings Call
27 May '24
Publication of Financial Re...
27 May '24
Investor Presentation
25 May '24
Financial Results
25 May '24
Reappointment of Directors
25 May '24
US FDA Inspection Classific...
25 May '24
Investor Meeting Intimation
24 May '24
Earnings Call
17 May '24
Compliance Submission
14 May '24
Completion
10 May '24
Scheme of Amalgamation
6 May '24
FDA Inspection Completion
3 May '24
Statutory Order received
3 May '24
Acquisition Announcement
2 May '24
Order Received
2 May '24
Completion of Disposal
2 May '24
Investor Meeting
8 Apr '24
Investor Meeting
8 Apr '24
Accident in Unit 6
7 Apr '24
Management Change
7 Apr '24
Completion of US FDA Inspec...
5 Apr '24
Compliance Certificate
4 Apr '24
Compliance Certificate
4 Apr '24
Postal Ballot Notice
4 Apr '24
Certificate submission
2 Apr '24
Commercial Production Comme...
31 Mar '24
Agreement Extension
28 Mar '24
Directorate Change
27 Mar '24
Newspaper Publication
20 Mar '24
USFDA Approval
19 Mar '24
Major Product Launch
15 Mar '24
Investor Presentation
13 Mar '24
Restarting Distribution
12 Mar '24
Compliance Accepted
11 Mar '24
Investor Media Meeting
6 Mar '24
Investor Meeting Update
6 Mar '24
Management Change
5 Mar '24
USFDA Approval
1 Mar '24
Production Restart
29 Feb '24
US FDA Inspection Completion
29 Feb '24
Investor Meet Intimation
28 Feb '24
Investor Meet Participation
28 Feb '24
Participation in Investor /...
26 Feb '24
Publication Notice
23 Feb '24
Earnings Calls
16 Feb '24
US FDA Inspection
16 Feb '24
USFDA Approval for Deflazac...
12 Feb '24
Audio Recording Uploaded
12 Feb '24
Newspaper Publication
12 Feb '24
Financial Results Announcement
10 Feb '24
Earnings Presentation
10 Feb '24
Change in Directorate
10 Feb '24
Regulatory Action
9 Feb '24
Investor/Analyst Meet
8 Feb '24
Participation in Investor /...
8 Feb '24
Investor/Analyst meet
8 Feb '24
Earnings Call
5 Feb '24
Disposal of Business Assets
5 Feb '24
FDA Inspection Completion
2 Feb '24
FDA Inspection Update
1 Feb '24
Announcement
17 Jan '24
US FDA Inspection
8 Jan '24
Certificate Submission
4 Jan '24
USFDA Approval for Posacona...
27 Dec '23
Completion of Inspection
24 Dec '23
US FDA Inspection
20 Dec '23
Investor/Analyst Meet
18 Dec '23
Acquisition Completion
15 Dec '23
Investor Meeting
8 Dec '23
Participation in Investor /...
3 Dec '23
Pharma Approval
30 Nov '23
USFDA Approval for Darunavi...
29 Nov '23
Notice published in newspap...
25 Nov '23
Incorporation of new subsid...
22 Nov '23
Acquisition Completed
22 Nov '23
Completion Of Purchase
22 Nov '23
FDA Approval of Ryzneuta fo...
22 Nov '23
Demise of COO
21 Nov '23
Completion of FDA Inspectio...
17 Nov '23
Investor Meeting
16 Nov '23
Earnings Calls
15 Nov '23
Resignation of Independent ...
14 Nov '23
Investor/Analyst Meetings
14 Nov '23
Publication of Financial Re...
11 Nov '23
Recording Uploaded
10 Nov '23
Investor Presentation
9 Nov '23
Financial Results Announcement
9 Nov '23
Appointment of a Director
9 Nov '23
Acquisition of Theranym Bio...
9 Nov '23
Investor Conferences
31 Oct '23
USFDA Approval for Testoste...
23 Oct '23
Inauguration of manufacturi...
16 Oct '23
Contract Manufacturing Oper...
11 Oct '23
Compliance Certificate
11 Oct '23
Response to Clarification
3 Oct '23
Sale and Transfer of API Units
1 Oct '23
Completion of US FDA Inspec...
30 Sep '23
License Agreement with Hill...
27 Sep '23
Investor / Analyst meet
21 Sep '23
Completion of Inspection at...
20 Sep '23
Newspaper Publication
18 Sep '23
Acquisition of Marketing an...
12 Sep '23
US FDA Inspection Classific...
7 Sep '23
News Clarification
25 Aug '23
Analyst Calls
23 Aug '23
Merger or Acquisition Annou...
19 Aug '23
Financial Statements
18 Aug '23
Financial Statements
18 Aug '23
Regulatory Compliance
17 Aug '23
Investor Meetings
17 Aug '23
Analyst Meetings
17 Aug '23
Equity
16 Aug '23
Equity
16 Aug '23
Earnings Calls
14 Aug '23
Financial Statements
14 Aug '23
Analyst Calls
12 Aug '23
Financial Statements
12 Aug '23
Management Changes
12 Aug '23
Resignations
12 Aug '23
Announcement
5 Aug '23
Financial Statements
4 Aug '23
Pre-Market Approval
4 Aug '23
Financial Statements, Earni...
2 Aug '23
Equity
1 Aug '23
Financial Statements
30 Jul '23
Equity
26 Jul '23
Reorganizations
26 Jul '23
US FDA Inspection
26 Jul '23
Announcement
25 Jul '23
Procedural Observations
21 Jul '23
Voluntary action indicated
17 Jul '23
Equity
12 Jul '23
Equity
7 Jul '23
Certificate under Reg. 74 (...
7 Jul '23
Virtual Meetings
6 Jul '23
Analyst Meetings
6 Jul '23
Product Updates
4 Jul '23
Asset Acquisitions
3 Jul '23
Asset Sales
1 Jul '23
Analyst Meetings
29 Jun '23
Analyst Calls
29 Jun '23
Facility Restructuring
29 Jun '23
Participation in Meet
26 Jun '23
Investor/Analyst Meet
26 Jun '23
Asset Sales
25 Jun '23
Analyst Meet
23 Jun '23
Equity Investment
23 Jun '23
Investor Meeting
19 Jun '23
Analyst/Investor Meet - Int...
16 Jun '23
Management Changes
15 Jun '23
Investor Meetings
13 Jun '23
Participation in Investors ...
13 Jun '23
Participation in investors ...
8 Jun '23
In-person meeting
7 Jun '23
Financial Results
1 Jun '23
Financial Results Publication
29 May '23
Earnings Calls
29 May '23
Related Party Transactions
27 May '23
Asset Sales
27 May '23
Presentation
27 May '23
N/A
27 May '23
Regulatory Compliance
26 May '23
Earnings Call
19 May '23
Observations Received
19 May '23
Compliance Report Submission
17 May '23
Annual Secretarial Compliance
17 May '23
External Links:
BSE
NSE
Data:
Download
AI Assistant
Close
Aurobindo Pharma Ltd
2023
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.